Univariate analysis of risk factors for acute GVHD development
. | No. of cases . | No. of events . | Probability, % (95% confidence interval) . | P . |
|---|---|---|---|---|
| Patient age | ||||
| Younger than 50 y | 49 | 27 | 55 (41-69) | NS |
| 50 y or older | 51 | 31 | 60 (18-44) | |
| Donor age | ||||
| Younger than 50 y | 59 | 33 | 56 (43-69) | NS |
| 50 y or older | 41 | 25 | 61 (46-76) | |
| Sex | ||||
| Female donor | 49 | 29 | 59 (45-73) | NS |
| Male donor | 51 | 29 | 57 (43-70) | |
| CMV serologic status | ||||
| Seronegative pair | 17 | 12 | 71 (44-90) | NS |
| Other | 83 | 46 | 55 (44-66) | |
| ABO | ||||
| Major mismatch | 29 | 15 | 52 (34-70) | NS |
| Other | 71 | 43 | 61 (50-72) | |
| Diagnosis | ||||
| Hematologic malignancy | 69 | 37 | 54 (42-66) | NS |
| Other malignant disease | 31 | 21 | 68 (52-84) | |
| Disease status | ||||
| Standard risk | 20 | 9 | 45 (23-67) | NS |
| Advanced disease | 80 | 49 | 61 (50-72) | |
| Stem cell source | ||||
| Bone marrow | 46 | 21 | 46 (32-60) | .02 |
| PBSC | 54 | 37 | 68 (56-80) | |
| ATG dose infused during conditioning | ||||
| High | 45 | 18 | 40 (26-54) | .001 |
| Low | 55 | 40 | 73 (61-85) |
. | No. of cases . | No. of events . | Probability, % (95% confidence interval) . | P . |
|---|---|---|---|---|
| Patient age | ||||
| Younger than 50 y | 49 | 27 | 55 (41-69) | NS |
| 50 y or older | 51 | 31 | 60 (18-44) | |
| Donor age | ||||
| Younger than 50 y | 59 | 33 | 56 (43-69) | NS |
| 50 y or older | 41 | 25 | 61 (46-76) | |
| Sex | ||||
| Female donor | 49 | 29 | 59 (45-73) | NS |
| Male donor | 51 | 29 | 57 (43-70) | |
| CMV serologic status | ||||
| Seronegative pair | 17 | 12 | 71 (44-90) | NS |
| Other | 83 | 46 | 55 (44-66) | |
| ABO | ||||
| Major mismatch | 29 | 15 | 52 (34-70) | NS |
| Other | 71 | 43 | 61 (50-72) | |
| Diagnosis | ||||
| Hematologic malignancy | 69 | 37 | 54 (42-66) | NS |
| Other malignant disease | 31 | 21 | 68 (52-84) | |
| Disease status | ||||
| Standard risk | 20 | 9 | 45 (23-67) | NS |
| Advanced disease | 80 | 49 | 61 (50-72) | |
| Stem cell source | ||||
| Bone marrow | 46 | 21 | 46 (32-60) | .02 |
| PBSC | 54 | 37 | 68 (56-80) | |
| ATG dose infused during conditioning | ||||
| High | 45 | 18 | 40 (26-54) | .001 |
| Low | 55 | 40 | 73 (61-85) |
NS indicates not significant.